Last reviewed · How we verify
NCT05756959
Myopia Control Combined PBM With Myopic Defocus Lens in Children
NA trial testing PBM in Myopia, Progressive in 304 participants. Currently enrolling.
1 August 2027
Quick facts
| Lead sponsor | Beijing Airdoc Technology Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 304 |
| Start date | 12 December 2022 |
| Primary completion | 1 August 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- PBM
- Peripheral defocus spectacles
- Single vision spectacles
Conditions studied
- Myopia, Progressive — all drugs for Myopia, Progressive →
Sponsor
Beijing Airdoc Technology Co., Ltd.
Who can join
Adults 6 to 13, any sex, with Myopia, Progressive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the efficacy of myopi control with two methods: low lever red light and peripheral defocus spectacles with four groups and design with prospective, double-blind, randimized, and with control for 6 month.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05756959
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PBM
Trials testing the same drug.
- NCT07047248 — Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled · NA · not yet recruiting
- NCT05619133 — PBM Effects on Health and Well-being in Humans · NA · unknown
- NCT04248972 — Effects of Photobiomodulation in a Population Suffering From Fibromyalgia · NA · completed
- NCT04425330 — Effects of Physical Therapy Associated With Photobiomodulation on Myelomeningocele · NA · unknown
Other recruiting trials for Myopia, Progressive
Currently open trials in the same condition.
- NCT06927388 — Myopia Progression With Freeform Myopia Control Spectacles · NA · active not recruiting
- NCT07055815 — Impact of Digital Screen Time in Progression of Myopia in Children · active not recruiting
- NCT06389110 — Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elo · Phase 3 · recruiting
- NCT06647160 — Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control · NA · active not recruiting
- NCT06520124 — Stellest Lens Wear in Adult Progressing Myopes · NA · active not recruiting
Other Beijing Airdoc Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT06059521 — Software Refraction With Mobilerone Versus Retinoscopy · NA · recruiting
- NCT05881655 — Slow Myopia Progression With Different Irradiance Light · NA · unknown
- NCT05761379 — Clinical Study of Light Therapy to Control Myopia Progression in Children · NA · unknown
- NCT05811598 — Real Word Study on Myopia Control With Repeated Red Light Therapy for Ages of 3~6 Years Old · NA · unknown
- NCT06088225 — Myopia Preventing With Distance-image Screen · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05756959 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Airdoc Technology Co., Ltd.
- Last refreshed: 9 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05756959.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing